ACRIN 6673

Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients

CRF Set



ACRIN Adverse Event Form

ACRIN Study	Case #
PLACE LAB	EL HERE
Institution	Institution No
Participant Initials	Case No

All questions regarding Adverse Events should be directed to ACRIN. All Adverse Events (AEs) and Serious Adverse Events (SAEs) as defined in the protocol require routine reporting via web entry of the AE CRF. In addition, <u>SAEs meeting the criteria for expedited reporting</u>, as specified in the protocol, require (a) telephone report to both NCI and ACRIN within 24 hours of knowledge, (b) AdEERS report completed and submitted as specified in the protocol, and (c) completed AE case report form with investigator's signature submitted to ACRIN via web and filed in the participant chart.

			CTCAE Grade	Attribution		AdEERS Submitted for SAEs	Action Taken	Outcome	Date of AE Onset and Resolution
	AE Description	AE Short Name CTCAE v3.0	1 = Mild 2 = Moderate 3 = Severe 4 = Life threatening	1 = Unrelated 2 = Unlikely 3 = Possible 4 = Probable	= Expected 2 = Unexpected	1 = No 2 = Yes	1 = None 2 = Medication Therapy 3 = Procedure 4 = Hospitalization	1 = Recovered $2 = Improved$ $3 = Ongoing$ $4 = Death$	(mm-dd-yyyy); check box "on-going" if the AE is on-going at the time of report
			or disabling 5 = Fatal	5 = Definite	7 = 7 =		4 = Hospitalization 5 = Other	5 = Unknown	I On-going
									Start date:
1									Resolution date:
									On-going
									Start date:
2									Resolution date:
									On-going
									Start date:
3									Resolution date:
									On-going
	nents - for each comment, identify t	sit,	e (#1-3):	1				1	I
	check this box and use another fo < <page of<="" td=""><td></td><td>r Signature</td><td></td><td></td><td></td><td>Date</td><td>Form Comple</td><td>eted (mm-dd-yyyy)</td></page>		r Signature				Date	Form Comple	eted (mm-dd-yyyy)
	ght 2005"		· e.g.a.a.e				Date		AE 01-18-05 1 o

TL ACRIN 6673	ACRIN Study 6673 PLACE LABEL HERE
Treatment Labs	Institution Institution No
If this is a revised or corrected form, indicate by checking box.	Participant Initials Case No
	sion by the Study Interventional Radiologist. Report all d <i>"prior"</i> to ablation session. Pages 3 and 4 are completed
1. Date of RFA session:	Date 10
2. Aspirin and nonsteroidal anti-inflammatory MU medications, antiplatelet medications, or warfarin discontinued prior to the procedure, per Sec 5.3.8 0 No, specify reason: 0 Yes 0 Participant not taking these medications	
3. Low molecular heparin discontinued 12 hours prio to RFA session, per Sec. 5.3.9 0 No, specify reason: 5 0 Yes 0 Participant not taking heparin	or സასჩეს (STOP, SIGN and DATE form. RFA treatment <u>may not</u> commence)
 4. Pregnancy test performed, per Sec. 5.3.7.? Multiple 0 No, specify reason:	(STOP, SIGN and DATE form. RFA treatment <u>may not</u> commence)

TL	ACRIN 6673 Treatment Labs	Revision	AC PLACE	RIN Study 6673 E LABEL HERE	
5. PRE-	RFASESSIONLABORATORY			Institution No	
	[Performed within 14 dates and the second se	ays prior to RFA]	Participant initials	Case No	
3 dor 98 not	ie, abnormal elevated ne, abnormal depressed done snown	Column, reco	rd unit of measure in field pro	that prompted within the Lab Value ovided. If unit reports are the same <u>Unit of Measure</u>) is to be left blank.	
	valuation Lab Value	Other of Unitof	Date of test (mm-dd-vyvy) (date is required for all labs)	<u>Normal Range</u> LOWHIGH	
√ multipi	Ll= Number lengt	A Measure	Dott 10	(required for all (required for all abnormal results) abnormal results)	
		Character 10	11	(-Number of length 4- 12 13	
		xonds	<u> </u>	18 19	
20			λ3 - ·	14	flort
ab		200 28	29	30 31	/ 5
32	Serum 33 L mg/d		35		
	Creatinine		<u> </u>	/	
1381	GGT 39 U/	. [40]	41		umber
1441		46	47	<u>48 / 49)</u>	of the
150		/mL <u>52</u>	53	54 > 55 >	float
5e	sgot 57 и	1 <u>58</u>	<u></u>		number
62	SGPT		<u>65</u> - <u>-</u> -	_ 66 7 67	ot 4
68	Total bilirubin	L 70	<u> </u>	72 72 72	quat 5
1141	Sodium 75 m	101/L 16		- 78 7 79 7	rumber flength
80	Potassium		<u> </u>	P4 - 85.7	+ 47
186	-	not/L 88	<u> </u>		number
1931	Glucose 93 mg		<u>45</u>	- 96 - 97	of length 4
198	BUN 99 mg	/dL 100	<u> 101</u> - <u> </u>	102 / 103	·
19			<u>107</u>	108 109	. 1-
110	Phosphorus L mg/d		<u> </u>	— тин / те).	floot
116	Total Protein		119	<u> 120 / 121 /</u>	
المهل		124	125	120/127/	wher of
128	Ammonia		<u>131</u>	132 138 - 138 - nu	
			137	- 138 7 139 7 AD	at 5
140	Hct [14] %			- 144 - 145 yrun	ength y
Ho	Wbc 147 К	ur [148]		<u>150 151 7 10</u>	ats

"copyright 2005"

ACRIN 6673 TL 11-01-05 2 of 4

TL	ACRIN 6673 Treatment Labs	Revision	ision D ACRIN Study 6673 PLACE LABEL HERE		
6. POS	T-RFASESSION LABORATOR	YEVALUATIONS:	Institution	Institution N	lo
	ormed within two hours after at πe, within normal limits	lation procedure.]	Participant Initials	Case No	
3 do 98 no	ne, abnormal elevated ne, abnormal depressed t done known	Column, rec	s: If lab units are other than ti ord unit of measure in field pro ompted, then Column III (<u>Other</u>	vided If unit report	s are the same
<u>Labs E</u>	valuation Lab Value	<u>Other</u> <u>Unitof</u> <u>Measure</u>	<u>Date of test (mm-dd-vyyy)</u> (date is required for all labs)	Normal Range LOW (required for all abnormal results)	Normal Range HGH (required for all abnormal results)
152	Platelets 153 Ku/		155	156	157
158	рт 159 Ш. Ц зесс	nds 160	161	162	163
164		nds 166	167	168	169
170	INR 171 []. [] %	172	173	174	175
لالم	Serum 177 L mg/dL Creatinine	178	<u>179</u>		181
182	GGT 183 WL	184	185	(86	187
188		1901	191		193
494		nL 196	197		199
200		Laon	<u>203</u>	act	205
206	SGPT 207 U/L	208	<u>209 · ·</u>	_	211
aiz		LAH	<u>215</u>	216	<u>217</u>
a18	Sodium 219 mm	1/L [220]	221	222	223
994	Potassium	adp 1	<u>201</u>	228	229
230		ML [332]	<u>}33</u> -	<u>234</u>	235
\$36	Glucose 337 mg/	1L 28	239	240	241
243	BUN 243 mg/	1 <u>244</u>	<u>a45</u>	<u>a46</u>	247
1248		1 250	251	<u>_252</u>	253
1354	Phosphorus	256	257	258	259
260	Total Protein	262	<u>263</u> -	864	265
		268	àut	270	271
272	Ammonia 273 µmo	n 1274	<u>275 </u>	276	277
178	11gb 279 g/dL	280	ــــــــــــــــــــــــــــــــــــــ	282	283
284	Het 285 4	286	281 · ·	288	289
1290	Woc 291 L Kui	292	293	294	295

"copyright 2005"

ACRIN 6673 TL 11-01-05 3 of 4

TL	ACRIN 6673 Treatment Labs	Revision	ACRINS PLACE LA	tudy 6673 ABEL HERE
	l		Institution	Institution No
			Participant initials	Case No
Comme	nts: 296	- Character	60	
	·····			
				298 Date 10
	297 - cha	Hacter D.S	Date form compl	eted ³ (mm-dd-yyyy)
Signatur	e of Person Responsible	for the date '		(mm-dd-yyyy)
	299 Charge	tr 25		
Signatur	e of person entering data			
"copyrigh			ACRIN	5673 TL 11-01-05 4 of 4

•

TC ACRIN 6673 Telephone Contact	ACRIN Study 6673 PLACE LABEL HERE Institution		
If this is a revised or corrected form, indicate by checking box	Participant Initials		
This form is to be completed by the Research Associate at This form is to be completed at 1 Day, 1 Week, 1 Month			
D. Date of evaluation: Date 10	3d. Cause of death:MultipleO t Progressive/persistent cancerO 2-Complications of protocol treatment		
2. Reason for contact: Multiple O 1 day post ablation O 21 week post ablation O 31 month post ablation	03Progressive cirrhosis Og Other, specify: <u>(9)Character</u> OggUnknown (40)		
०५३ months post ablation 2a. Date of last RFA session:	4. Performance status (Zubrod Scale) Multiple 01 Fully active 02 Ambulatory, capable of light work		
3. Participant status: Multiple (4) O + Alive (Proceed to Q4)	O 3 In bed less than 50% of the time, capable of self-care, but not of work activities O식In bed greater than 50% of the time,		
O 2 Transplanted (Complete 3a) O 3 Dead (Complete 3b, 3c, and 3d) O 4 Lost to follow-up; unable to contact (complete 3c)	capable of only limited self care O 5 Bedridden O 6 Not evaluated		
3a. Date of transplant:	OpeUnknown 5. Are there any reportable complications/adverse Image: Complete the section of the protocol? OI NO Multiple OLYes (If yes, an AE form must be completed		
() 3c. Date of last contact: Date 10 (mm-dd-yyyy)	RECEIVED OCT 1 3 2005		
Comments: (2) character - 60	AORIN		
(13) Character 25 Signature of Site Principal Investigator	Date form completed 3 (mm-dd-yyyy)		
Signature of person entering data onto the web ²			
"copyright 2005"	ACRIN 6673 TC 10-11-05		

PO RFA-HCC	ACRINS PLACE LA	tudy 6673 ABEL HERE
ACRIN Consensus Pathology Read	Institution	Institution No
If this is a revised or corrected form, indicate by checking box	Participant Initials	Case No
Instructions: This form is completed by the Alternate		
	ACRIN Pathologist.	
1. Interpretation Date		
2. Specimen type (select one)		
To I FNA		
o ² Core Needle Biopsy o ³ Resected Hepatic Tissue		
C Resected Hepatic Tissue		
2a. Specimen ID#:		
3. Findings		
3a. Presence of hepatocellular carcinoma (HCC)		
o (Not present (Stop, sign, and date form) (4) o $\frac{2}{3}$ Present		
o ³ Equivocal		
3b. Nuclear grade		
011		
o 4 IV		
3c. Growth pattern (check all that apply)		
φ 🔲 Trabecular		
☐ Psuedoglandular ✓ □ Compact		
9 🔲 Fibrolamellar		
lò □ Scirrhous		
i Mixed		
Comments:		
	·······	and a second
\sim		
(13)	Date form complete) od ³ –
Signature of person entering data onto the web ¹	Date form complete	ed * = = (mm-dd-yyyy)
(15)		
Printed name of pathologist ²		
copyright 2005"		6673 PO 10-25-05 1 of 1

P-7-2006 08:30A FROM:TINA TAYLOR (43	34)296-3102 TO:12157170936 P.4
DI ACRIN 6673	ACRIN Study 6673
RFA-HCC	PLACE LABEL HERE
Local Pathology Interpretation	Dn Institution Institution No
If this is a revised or corrected form, please $\sqrt{ ext{box}}$.	Participant Initials Case No
	in the data that questions
- 6 under Part A were completed. After completion of Part A, t	sociate. 'Date form completed' under Part A is the date that questions the form and pathologic material are sent to the local pathologist. Part eted' under Part B is the date that questions 1 - 5a under Part B were parate form is submitted for each tumor.
Part A (completed by site Research Associate)	Part B (completed by the local Pathologist)
1. Procedure Date:	Interpretation Date:
)	(A)
(mm-dd-yyyy)	(mm-dd-yyyy)
	2. Specimen type (select one)
2. Type of Procedure (select one)	(A) OI FNA
o FNA o & Core Needle Biopsy	- og Core Needle Blopsy
3 Resected Hepatic Tissue	o3 Resected Hepatic Tissue
	3. Specimen ID # <u>AI</u>
3. Couinaud Segment Location	
(check all that apply for this tumor)	4. Findings 4a. Presence of hepatocellular carcinoma (HCC)
3 🔲 Segment I	() which are not folder the and to)
+ 🛄 Segment II	o t Not present (skip 4b and 4c) og Present
5 🗋 Segment III	o ڪ Equivocal
🗘 🗌 Segment NA	4b. Nuclear grade
7 📙 Segment IVB	
🎖 🗖 Segment V	
9 🗆 Segment VI	03 11
N 🗆 Segment VII	out N o c Unable to determine
t 🗌 Segment VIII	
Specimen ID # (IA)	4c. Growth pattern (check all that apply)
5. Slide ID #13	AS Psuedoglandular RECEIVE
	20 Compact
5. Tumor # (14)	a7 Fibrolamellar SEP 07 2
	Av Scirrhous
	33 Unable to determine
	(A)
omments:	Comments:
	~
	Date form completed ³ 3
ignature of person responsible for the data ¹	Date form completed * (mm-dd-yyyy)
Buarare of herson responsible for the data .	
	(32)
ate form completed 3 UF	Printed name of pathologist
(mm-dd-yyyy)	
(8)	
ignature of person entering data on to the web ²	6673 PL 8-29-06 1 of 1


Ρ.3

P4 ACRIN 6673 RFA-HCC	ACRIN Study 6673 PLACE LABEL HERE
ACRIN Central Pathology Interpretation	Institution Institution No
	Participant Initials Case No
If this is a revised or corrected form, please \sqrt{box} .	
Instructions: Part A is to be completed by the Research Associate. After c Part B. Part B will be completed by the Core Pathologist based on the patholo the P4 form and the P1 (pathology report) should be mailed to ACRIN 6664 Data N form is submitted for each tumor.	nic material available. At the time of side subinission a copy of the rootering
Part A (completed by site Research Associate)	Part B (completed by the ACRIN Pathologist)
1. Procedure Date: D	1. Interpretation Date: IF
 Date Specimen sent to Core Lab: (mm-dd-yyyy) Couinaud Segment Location (check all that apply for this tumor) 	2. Specimen type o I FNA o 2 Core Needle Biopsy o 3 Resected Hepatic Tissue 3. Specimen ID #
3 Segment I 4 Segment II 5 Segment III 6 Tumor #	 4. Findings 4a. Presence of hepatocellular carcinoma (HCC) a) It is that a state of the state o
Comments:	Comments:
Completed by (Site RA):	Date form completed

"copyright 2006"

ACRIN 6673 RFA Hepatocelluar Carcinoma	ACRIN Study 6673 PLACE LABEL HERE
Initial RFA Treatment Form	Institution Institution No
If this is a revised or corrected form, indicate by checking box.	Patient's Initials Patient's I.D. No
Instructions: This form collects information related to th report dates mm/dd/yyyy. If a response is unknown, reco	
1 Did the RFA treatment commence?	3b If RFA did not commence or was
1 No (complete 1a)	not completed, specify reason:
2 Yes	O 1 Patient refused to start treatment
Lesion 1	O 2 Technical problems during procedure
Lesion 2	O 3 RFA treatment initiated but not completed
Lesion 3	O 4 RFA treatment not initiated
3 Not applicable	O 5 Adverse event or toxicity, specify:
5 Not applicable	
 1a If RFA treatment did not commence, specify reason wh O 1 Patient refused to start treatment 	y: O 6 Other reason, specify:
O 2 Technical problems	4 **Number of tumors treated:
O 3 Adverse event or toxicity, specify:	0 1 0 2 0 3
O 4 Other reason, specify:	**[Complete an Ablation Treatment Form per tumor treated - see pages 3-5.]
 1b Were any adverse events reported during this time period: 0 1 Yes 0 2 No If <u>yes</u>, specify date: 	 5 Radiologist ID performing procedure: 6 Imaging modality utilized for RFA 0 1 Ultrasound 0 2 CT Scan 0 3 MRI
	7 Was a pregnancy test performed
2a Date of biopsy	(BetahCG blood test) within 24 hours prior to
(mm-dd-yyyy)	RFA procedure?
2b Type of procedure:	O 1 No (complete 7a)
O 1 FNA	O 2 Yes (complete 7b)
O 2 Core Needle Biopsy	O 3 Not applicable
3 Date of RFA treatment (mm-dd-yyyy)	7a If no specify:
3a Was the RFA treatment completed for each tumor?	
1 No (complete 3a)	
2 Yes	7b Test results:
Lesion 1	O 1 Negative
Lesion 2	O 2 Positive
Lesion 3	
3 Not applicable	


8 Complete description of <u>each tumor ablated</u> and indicate location using the diagram, (Appendix VI). Numbering must be consistent throughout the study.



*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

Diagram of the Liver



TF Stu	dy 6673	Case #		Revision
	ecord tumor numb	er per diagram) is session within this tu	9d. Indicate Valley LRf Ablation needo 1 single, 2 cmo 2 single, 3 cmo 3 cluster, 3 pro	les utilized: tip tip
	f cauterizations for 2 0 3 0 4		9e. Were any compl o No o Yes <u>If yes, check all t</u> o abcess o hemorrahage o other, specify:	o pneumothorax
Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions
1				
2				
3				
4				
5				
6				
7				
8				

Diagram of the Liver

*Couinaud Segments


1 Segment I

9

10

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

9f. Mark location cauterizations on diagram with a "c".



TF Stu	udy 6673	Case #		Revision			
	tment Form LE SKIP AND COMPLE Record tumor numb		10d. Indicate Valley L Rf Ablation needl o 1 single, 2 cm t o 2 single, 3 cm t o 3 cluster, 3 pror	es utilized: ip ip			
o Not app 10b. Number o			o No o Yes <u>If yes, check all th</u> o abcess	10e.Were any complications encountered?o No o YesIf yes, check all that apply:o abcesso pneumothoraxo hemorrahageo tumor seeding			
Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions			
1							
2							
2							
2 3							
2 3 4							
2 3 4 5							

Diagram of the Liver

*Couinaud Segments


1 Segment I

9

10

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

10f. Mark location cauterizations on diagram with a "c".



	Stu	udy 6673	Case #		Revision
Ablati	ion Trea	tment Form		11d. Indicate Valley I	ab Cooled Tip
IFNOT	APPLICAB	LE SKIP AND COMPL	ETE LAST PAGE]	Rf Ablation needl	-
				o 1 single, 2 cm t	ip
11. Tur	mor 📙 (F	Record tumor num	ber per diagram)	o 2 single, 3 cm t	ip
				o 3 cluster, 3 pro	ng, 2.5 cm tip
11a.	Nu	mber of ablations	this session within this tu	umor 11e. Were any comp	lications encountered?
	o Not ap	plicable		o No o Yes	
				<u>lf yes, check all ti</u>	<u>hat apply:</u>
11b.	Number	of cauterizations for	or this tumor:	o abcess	o pneumothorax
	o 1 o	2 03 04	05 06	o hemorrahage	o tumor seeding
				o other, specify:	
	Ablation	Baseline	Treatment Duration	One Minute Post Treatment	Number of
	Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)		Number of Needle Insertions
	Number			One Minute Post Treatment	
	Number 1			One Minute Post Treatment	
	Number 1 2			One Minute Post Treatment	
	Number 1 2 3			One Minute Post Treatment	

Diagram of the Liver

*Couinaud Segments

1 Segment I

7


8

9

10

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

11f. Mark location cauterizations on diagram with a "c".



TF	Study 6673	Case #		Revision
Comments:				
			Date form completed ³	
Signature of	f person responsible for the data ¹			(mm-dd-yyyy)
Cignature	norman antoring data anto the	2		
Signature of	person entering data onto the web	2		

RFA-HCC Additional RFA Session Form	ACRIN Stud PLACE LAP	-							
		Institution	_ Institution No						
If this is a revised or corrected form, please \sqrt{box} .		Participant Initials	_ Case No						
Instructions: The Additional RFA Session Form (RA) is to be completed by the Study Radiologist (the radiologist performing the RFA), for tumors ablated after the initial ablation session. A RA Form is completed for each tumor ablated. The ablated tumor and cauterization locations are marked within the diagrams (page 2, question 6b) with a "t" and "c" within the appropriate segment. Once the form data has been entered into the ACRIN website www.acrin.org a copy of page 2 of the RA form must be mailed to the Data Management Center A case specific label should be affixed to the form in the designated area.									
 1. Did RFA session commence for this tumor? [110] (Complete one RA from per tumor) No (Complete Q1a - 2d, then sign and date form) Yes (Proceed to Q2) 1a. If no give reason: [111] Participant refused Technical problems during procedure RFA deferred Adverse Event Claustrophobia Complications, specify:[112] Medical reason Equipment failure Injection site complications Unable to visualize lesion Other reason, specify:[113] 1b. How many tumors were scheduled to be treated?[114] 1c. This form represents tumor number:[116] O No Yes 	O CT O Biop 2b. Date of C 2c. Date of b 2d. Type of pr O FNA O Cor 3. Date of RFA 3a. Reader IE 4. Total number (Complete one 4a. This form 4b. Imaging n O Ultr	e needle biopsy session: of tumors treated this session: e RA form per tumor) represents tumor number: nodality used for RFA: [10] asound scan	(mm-dd-yyyy) _[4]						
 2. Type of recurrence (select one) [1] O Local (faliure of primary ablation) O Remote intrahepatic O Both 	Sec. 15.0 of O No	y reportable complications / a the protocol? [11] s (AE form must be completed)	dverse events per						

RFA-HCC Additional RFA Session Form If this is a revised or corrected form, please \sqrt{box} . ABLATION SESSION FORM	ACRIN Study 6673 PLACE LABEL HERE Institution Institution No Participant Initials Case No
Tumor location and numbering must remain consistent throughout study.	
 6. This form represents Tumor Number [12] 6a. Date of Session: (mm-dd-yyyy) [13] 6b. Mark location of this tumor number and cauterization with a "t" and "c" respectively on the diagram below. 	 6c. Was the RFA session completed or attempted for this tumor? [14] O No, RFA not completed, no RFA treatment to record (Complete 6d, sign and date form) O Yes, RFA complete (Proceed to Q7) O Yes, RFA attempted and incomplete (Complete 6d and proceed to Q7) 6d. If RFA was not completed, specify reason: [15]
<section-header></section-header>	 Participant refused Technical problems during procedure RFA deferred Adverse Event Claustrophobia Complications, specify: [117] Medical reason Equipment failure Injection site complications Unable to visualize lesion Other reason, specify: [16]
	Couinaud Segments:Segment ISegment IISegment IVASegment IVBSegment VASegment VIISegment VISegment VIII

RFA-HCC Additional RFA Session Form	ACRIN Study 6673 PLACE LABEL HERE					
If this is a revised or corrected form, please \sqrt{box} .	Institution		Institution No			
Ablation Session Form						
7. Complete description of this tumor						

Assigned Tumor Number	Record Session Date	Couinaud Liver Segment (Check all that apply for this tumor)	Size (cm) Largest Size in Diameter	Subcapsular	Contiguous to Major Vessels? (vessels > 5mm)	Number of ablations this session within this tumor	Number of percutaneous punctures during this session
	[18] 20 (mm-dd-yyyy)	Segment I[19]Segment II[20]Segment III[21]Segment IVA[22]Segment IVB[23]Segment V[24]Segment VI[25]Segment VII[26]Segment VIII[27]	[28] Note: Lesion size recorded on C2 or NT form(s) must remain consistent throughout the study on RA forms.	[29] O No O Yes	[30] O No O Yes	[31]	[32]

RFA-HCC Additional RFA Session Form	ACRIN Study 6673 PLACE LABEL HERE		
If this is a revised or corrected form, please \sqrt{box} .	Institution	Institution No	
	Participant Initials	Case No	

Note: Required ablations (as per Section 9 of the protocol) less than 12 minutes (16 minutes if using switchbox) will be considered non-compliant according to Section 20.6 of the protocol.

Ablation Number	Baseline Impedance (R)	Treatment Duration (min)	One minute Post Treatment Temperature (C)	Switch box used?	Switch box cycle number	Indicate Valley Lab Cooled Tip RF ablation needles utilized	Cauterization of needle track performed? If yes indicate location on diagram with a "c"	Number of tumors ablated utilizing switch box	Assigned tumor number of tumors ablated utilizing Switch box (check all that apply)	Are there additional ablations to describe for this tumor?
1.	[35]	[36]	[37]	[38] O No O Yes	[39] O 1 O 4 O 2 O 5 O 3	[34] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	[33] O No O Yes	[118] O 1 O 4 O 2 O 5 O 3 O 6	[119] 1 5 9 2 6 10 3 7 11 4 8 12	[40] O No O Yes
2.	[41]	[42]	[43]	[44] O No O Yes	[45] O 1 O 4 O 2 O 5 O 3	[120] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	[121] O No O Yes	[122] O 1 O 4 O 2 O 5 O 3 O 6	[123] 1 5 9 2 6 10 3 7 11 4 8 12	[46] O No O Yes
3.	[47]	[48]	[49]	[50] O No O Yes	[51] O 1 O 4 O 2 O 5 O 3	[124] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	[125] O No O Yes	[126] O 1 O 4 O 2 O 5 O 3 O 6	[127] 1 5 9 2 6 10 3 7 11 4 8 12	[52] O No O Yes
4.	[53]	[54]	[55]	[56] O No O Yes	[57] O 1 O 4 O 2 O 5 O 3	[128] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	[129] O No O Yes	[130] O 1 O 4 O 2 O 5 O 3 O 6	[131] 1 5 9 2 6 10 3 7 11 4 8 12	[58] O No O Yes
5.	[59]	[60]	[61]	[62] O No O Yes	[63] O 1 O 4 O 2 O 5 O 3	[132] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	[133] O No O Yes	[134] O 1 O 4 O 2 O 5 O 3 O 6	[135] 1 5 9 2 6 10 3 7 11 4 8 12	[64] O No O Yes
6.	[65]	[66]	[67]	[68] O No O Yes	[69] O 1 O 4 O 2 O 5 O 3	[136] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	[137] O No O Yes	[138] O 1 O 4 O 2 O 5 O 3 O 6	[139] 1 5 9 2 6 10 3 7 11 4 8 12	[70] O No O Yes

"Copyright 2007"

RFA-HCC Additional RFA Session Form	ACRIN Study 6673 PLACE LABEL HERE		
If this is a revised or corrected form, please \sqrt{box} .	Institution	Institution No	
	Participant Initials	Case No	

Note: Required ablations (as per Section 9 of the protocol) less than 12 minutes (16 minutes if using switchbox) will be considered non-compliant according to Section 20.6 of the protocol.

Ablation Number	Baseline Impedance (R)	Treatment Duration (min)	One minute Post Treatment Temperature (C)	Switch box used?	Switch cycle n		Indicate Valley Lab Cooled Tip RF ablation needles utilized	Cauterization needle tract performed? If yes indice location on diagram w	k cate	ablate	r of tumors d utilizing tch box	of to utilizi	ed tumor umors abl ing Switc k all that	ated h box	Are there additional ablations to describe for this tumor?
7.	[71]	[72]	[73]	[74] O No O Yes		[75] O 4 O 5	[140] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	O No O Yes	[141]	O 1 O 2 O 3	[142] O 4 O 5 O 6	□ 1 □ 2 □ 3 □ 4	☐ 5 ☐ 6 ☐ 7 ☐ 8	[143] 9 10 11 12	[76] O No O Yes
8.		[78]	[79]	[80] O No O Yes			[144] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	O No O Yes	[144]	O 1 O 2 O 3	[146] O 4 O 5 O 6	□ 1 □ 2 □ 3 □ 4	☐ 5 ☐ 6 ☐ 7 ☐ 8	[147] 9 10 11 12	[82] O No O Yes
9.	[83]	[84]	[85]	[86] O No O Yes		0 -	[148] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	O No O Yes	[148]	O 1 O 2 O 3	[150] O 4 O 5 O 6	□ 1 □ 2 □ 3 □ 4	☐ 5 ☐ 6 ☐ 7 ☐ 8	[151] 9 10 11 12	[88] O No O Yes
10.	[89]	[90]	[91]	[92] O No O Yes		[93] O 4 O 5	[152] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	O No O Yes	[152]	O 1 O 2 O 3	[154] O 4 O 5 O 6	□ 1 □ 2 □ 3 □ 4	□ 5 □ 6 □ 7 □ 8	[155] 9 10 11 12	[94] O No O Yes
11.	[95]	[96]	[97]	[98] O No O Yes		05	[156] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	O No O Yes	[156]	0 1 0 2 0 3	[158] O 4 O 5 O 6	□ 1 □ 2 □ 3 □ 4	□ 5 □ 6 □ 7 □ 8	[159] 9 10 11 12	[100] O No O Yes
12.	[101]		[103]	[104] O No O Yes	O 1	05	[160] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip	O No O Yes	[160]	0 1 0 2 0 3	[162] O 4 O 5 O 6	□ 1 □ 2 □ 3 □ 4	□ 5 □ 6 □ 7 □ 8	[163] 9 10 11 12	


"Copyright 2007"

RFA-HCC Additional RFA Session Form	ACRINS PLACE L	udy 6673 ABEL HERE	\int
If this is a revised or corrected form, please \sqrt{box} .		Institution No	_
Comments:		Case No	
		[1	[106]
Signature of Person Responsible for the data	Date form completed	[108	8]
Signature of person entering data onto the web			
)

		N 6673 naging Foll	ow-up Fe	orm		RIN Study 6673
Ļ		00	•		Institution	Institution No.
	his is a revised m, indicate by ch]		Patient's Initials	Patient's I.D. No
Instru	Ictions: This form	n is completed by t	he Study Rad	liologist.		
1.	 0 0-3 month 0 3-6 month 0 6-9 month 0 9-12 month 0 12-15 morth 0 12-15 morth 0 15-18 morth 0 Other, specification 1a. Reason forther 0 Everyther 0 Post at 	ays of initial RFA T h nth	w-up:			
2.		A procedure: _	(mm-dd-	уууу)		
	2a. Tot O 1	tal number of tu O 3	mors treated O 5	l since e O 7	enrollment:	
	O 2	O 4		-		
3.	Date of imaging	g study:				
			(mm-aa-	уууу)		
4.	AFP drawn on aO NoO Yes (completeO Not application	ete 4a)	Scan?			
	4a. AFP la	b value	ng/ml			
5.		can meet the im he protocol, sec		a		
0 0	No (Answer 5a, s Yes	stop and sign forn	n)			
	5a. <u>If NO</u> , s	scheduled date o	f repeat CT:			
		(mn	n-dd-yyyy)			

IM


Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Checkall that apply for this tumor)	Are there additional ablated tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor Not technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision



Tumor Number Couinau Liver Segmen (Checkall that a for this tumor	intra-hepatic t* tumor status:	Patterns of recurrence:	Re-ablation indicated:	<u>If YES to Re-ablation</u> does this meet the f ollow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Check all that apply for this tumor)	Are there additional ablated tumors to describe?
□ Segment □ Segment □ Segment □ Segment □ Segment □ Segment □ Segment □ Segment	1 2 Tumor Present 11 88 Indeterminate VA	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahepatic tumor Not technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3	<u>If No to</u> <u>re-ablation</u> provide reason: (Check all that apply for this tumor)	Are there additional ablated tumors to describe?
	Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahepatic tumor Not technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Check all that apply for this tumor)	Are there additional ablated tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VIII □ Segment VIII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahepatic tumor Not technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the f ollow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Check all that apply for this tumor)	Are there additional ablated tumors to describe?
	Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor No technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Check all that apply for this tumor)	Are there additional ablated tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VIII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor No technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the f ollow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Checkall that apply for this tumor)	Are there additional ablated tumors to describe?
	Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor No technichally feasible Not clinically indicated 	1 No 2 Yes

IM


Revision




Tumor Number	Couinaud Liver Segment* (Checkall that apply forthis tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Checkall that apply for this tumor)	Are there additional ablated tumors to describe?
	Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor No technichally feasible Not clinically indicated 	1 No 2 Yes

IM

Revision



Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Local intra-hepatic tumor status:	Patterns of recurrence:	Re-ablation indicated:	<u>If YES to Re-ablation</u> does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3	If No to re-ablation provide reason: (Check all that apply for this tumor)
	Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII	1 Tumor Absent 2 Tumor Present 88 Indeterminate	1 Enlargement 2 Halo 3 Nodule	1 No 2 Yes 88 Indeterminate	1 No 2 Yes	 Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor No technichally feasible Not clinically indicated




Remote Intrahepatic Tumor

16. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA, provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

Revision




Remote Intrahepatic Tumor

17. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA, provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

Revision



Remote Intrahepatic Tumor

18. Number of New Tumor


Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA. provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

a

IVb

Revision



Ь

d

Couinaud Segments:						
Segment	I					
Segment	II					
Segment	III					
Segment	IVA					
Segment	IVB					
Segment	V					
Segment	N					
Segment	VII					
Segment	VIII					

Remote Intrahepatic Tumor

6 11


IVb

18. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check allthat apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA. provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

Revision




Remote Intrahepatic Tumor

19. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA, provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

Revision



Remote Intrahepatic Tumor

20. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA. provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

Revision

I

Ш

111

IVA


IVB

V

VI

VII

VIII



Remote Intrahepatic Tumor

21. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA, provide reason (Checkall that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment IVB □ Segment V □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM

Revision

I

Ш

III

IVA


IVB

V

VI

VII

VIII




22. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA, provide reason (Checkall that apply for this tumor)	Are there additional tumors to describe?
	Segment I Segment II Segment IVA Segment IVA Segment VI Segment VI Segment VII Segment VIII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes

IM


Revision



Remote Intrahepatic Tumor

23. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA, provide reason (Check all that apply for this tumor)	Are there additional tumors to describe?
	□ Segment I □ Segment II □ Segment III □ Segment IVA □ Segment V □ Segment VI □ Segment VII □ Segment VII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	1 No (Stop and sign form) 2 Yes



Remote Intrahepatic Tumor


24. Number of New Tumor

Tumor Number	Couinaud Liver Segment* (Checkall that apply for this tumor)	Largest size in diameter (cm)	Biopsy Indicated?	Does tumor meet the criteria for RFA treat- ment as outlined in the Protocol?	If No to RFA. provide reason (Checkall that apply for this tumor)	
Comments	Segment I Segment II Segment II Segment IVA Segment IVA Segment V Segment VI Segment VII Segment VII Segment VII Segment VII Segment VII SEgment VIII		1 No 2 Yes	1 No 2 Yes 88 Indeterminate	 Tumor Size exceeds 5 cm. Tumor adjacent to vital structures. Evidence of extrahepatic tumor Not technically feasible Not clinically indicated 	
Signature of person responsible for the data ¹					Date form completed	³ (mm-dd-yyyy)
	-	ing data onto th	e web ²			
"copyrigh	nt 2005"				ACRIN 6673	IM 06-22-05 20 of 2

ACRIN Study 6673 **ACRIN 6673 PLACE LABEL HERE RFA Hepatocellular Cancer Initial Evaluation Form** Institution _ Institution No. __ If this is a revised or corrected Patient's Initials Patient's I.D. No._ form, indicate by checking box. Instructions: Complete and submit this information at the time of the patient's entry to the study. Information reported is for observations and findings prior to the start of protocol RFA. All dates are mm/dd/yyyy unless specified otherwise. 4. Pre-enrollment imaging 1. Performance status (Zubrod Scale) (performed within 60 days of RFA treatment) O Fully active, able to carry on all O Not done predisease activities without restriction. O Done O Restricted in physically strenuous activity O Unknown but ambulatory and able to carry out work of a light or sedentary nature. <u>Imaging</u> Date O Ambulatory and capable of all self-care but unable to carry out any work activities. Abdominal CT O Capable of only limited self-care, (mm-dd-yyyy) confined to bed or chair 50% or more of waking hours. Hepatic Ultrasound O Completely disabled (mm-dd-yyyy) (If performed) O Unknown Chest CT (mm-dd-yyyy) 2. Diagnosis of Cirrhosis (Check all that apply) O Negative for metastatic disease Biopsy proof O Positive for metastatic disease Date of biopsy: ____ - ___ (mm-dd-yyyy) Type of procedure Other, specify_____ FNA Core Needle Biopsy (mm-dd-yyyy) Clinical and imaging confirmation 5. Prior treatment for HCC: O No 3. Confirmation of Hepatocelluar carcinoma (HCC) O Yes (Answer 5a) Biopsy proof Date of biopsy: 5a. If yes, specify treatment: _____ (mm-dd-yyyy) Type of procedure FNA 6. Patient a surgical candidate? Core Needle Biopsy (see Surgical Assessment Form, Appendix IX) O No Barcelona imaging criteria: O Yes Radiologic criteria [two coincidental imaging techniques (CT, MRI, US, angio) showing > 2 cm arterial enhancing tumor nodule Combined criteria [single imaging technique (CT, MRI, US, angio) showing > 2 cm arterial enhancing tumor nodule with AFP > 400 ng/mL Tumor growth criteria

	CRIN 6673 RFA Hepato	cellular Cance	Case # Revisio		
[Per 1 don 2 don 3 dor 98 not	eline Laboratory E formed within 14 c ne, within normal li e, abnormal eleva ne, abnormal depr done nown	lays prior to RFA] mits ted			
Pre-Re	egistration Ba	aseline			
<u>Labs</u>		<u>Lab Value</u>	Date of test (mm-dd-yyyy) (date is required for all labs)	Normal Range LOW (required for all abnormal results)	Normal Range HIGH (required for all abnormal results)
	Platelets	ml	··		
	PT	seconds	··		
	PTT	seconds			
	INR	L. mg/dl	·		
	Serum Creatinine	L mg/dl	·		
	GGT	u/I	··		
	LDH	mg/dl	··		
	AFP	ng/ml	·		
	SGOT	u/I	··		
	SGPT	u/I	·		
	Total bilirubin	L. mg/dl	··		
	Sodium	meg/dl	·		
	Potassium		·		
	Chloride	mea/l	·		
	Glucose	mg/dl	• •		
	BUN	mg/dl			
	Calcium	L mg/dl	• •		
	Phosphorus	L mg/dl	• •		
	Total Protein	gm/dl	• •		
	Albumin	gm/dI	·		
	Ammonia	g/dl	• •		
	Hgb	g/dl	• •		
	Hct	ml/dl	·		
	Wbc	. k/mm³	·		

ACRIN 6673 Case #_____ RFA Hepatocellular Cancer - Initial Evaluation Revision Diagram of the Liver (Appendix VI) Image: Comparison of the Liver (Appendix



Ь

0	
Segment	II
Segment	Ш
Segment	IVA
Segment	IVB
Segment	V
Segment	VI
Segment	VII

Segment


VIII

NUMBER OF TUMORS PRESENT:

Complete description of each tumor and indicate location using the diagrams, (Appendix VI). Numbering must be consistent throughout the study.


Assigend Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Size (cm) Largest Size in Diameter	Are there additional tumors to describe?
	 Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII 		.1 No 2 Yes

8.



9. Complete description of each tumor and indicate location using the diagrams, (Appendix VI). <u>Numbering must be consistent throughout the study</u>.

Assigend Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Size (cm) Largest Size in Diameter	Are there additional tumors to describe?
	 Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII 		.1 No 2 Yes



Numbering must be consistent throughout the study.

Assigend Tumor Number	Couinaud Liver Segment* (Check all that apply for this tumor)	Size (cm) Largest Size in Diameter
	 Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII 	

Comments:_

- 20 Date form completed ³ _____ - ____ Signature of person responsible for the data 1 (mm-dd-yyyy) Signature of person entering data onto the web² ACRIN 6673 I1 5 of 5 "copyright 2005" 06-22-05

FO ACRIN 6673	ACRIN Study 6673 PLACE LABEL HERE			
Additional RFA Treatment Form				
If this is a revised or corrected form, indicate by checking box	Patient's Initials			
Instructions: This form collects information related and report dates mm/dd/yyyy.	to the RFA Treatment. Use	code table when provided		
1. Tumor recurrence o No (skip to Q2) o Yes				
1a. Proof of recurrence o CT o Biopsy				
 1b. Type of recurrence o Local (failure of primary abalation) o Remote o Both 				
2. Date of RFA treatment:				
 Did the Re-ablation treatment commence? o No* (complete 3b) o Yes 				
 3a. Was the Re-ablation treatment completed? o No* (complete 3b) o Yes 				
 3b. *If RFA did not commence or was not completed, specify reason: o Patient refused to start treatment o Technical problems during procedure o Adverse event o Other reason, specify: 				
3c. Were any adverse events reported during this time period: O 1 Yes				
O 2 No If <u>yes</u> , specify date: (mm-dd-yyyy)				
4. Radiologist ID performing procedure:				
 5. Imaging modality utilized for RFA o Ultrasound o CT Scan 				
o MRI "copyright 2005"	ACRIN	6673 FO 06-08-05 1 of 11		


7 Complete description of <u>each tumor ablated</u> and indicate location using the diagram (appendix VI). Numbering must be consistent throughout the study.

Assigned Tumor #	Liver Segment *	Type of recurrent 1 Local 2 Remote	ce** Size (mm) Trans (M-L) x CC (S-I) x AP (A-P)	Subcapsular 1 No 2 Yes	Contiguous to major (< 1 cm) vessels 1 No 2 Yes	Number of previous RFA sessions

Diagram of the Liver Appendix VI

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



2 of 11

FO St	udy 6673	Case #		Revision		
Ablation Treatment Form 8. Tumor (Record tumor number per diagram) 8a. Number of ablations this session within this tumor 8b. Number of prior RFA sessions for this tumor			Rf Ablatio o 1 single o 2 single o 3 cluste 8e. Were any	 8d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: o 1 single, 2 cm tip o 2 single, 3 cm tip o 3 cluster, 3 prong, 2.5 cm tip 8e. Were any complications encountered? o No o Yes 		
8c. Number	 8b. Number of prior RFA sessions for this tumor 8c. Number of cauterizations for this tumor: 0 1 0 2 0 3 0 4 0 5 0 6 		<u>If yes, ch</u> o o abcess o hemorra o other, s	ahage o tumor seeding		
Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Trea Temperature(°C)	atment Number of Needle Insertions		
1						
2						
3						
4						

Diagram	of	the	Liver
---------	----	-----	-------

*Couinaud Segments

1 Segment I

5


6 7 8

9

10

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

8f. Mark location cauterizations on diagram with a "c".



Study 6673 Case # _____ Revision **Ablation Treatment Form** 9d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: [IF NOT APPLICABLE SKIP AND COMPLETE LAST PAGE] o 1 single, 2 cm tip o 2 single, 3 cm tip 9. Tumor (Record tumor number per diagram) o 3 cluster, 3 prong, 2.5 cm tip 9a. Number of ablations this session within this tumor 9e. Were any complications encountered? o No o Yes 9b. Number of prior RFA sessions for this tumor If yes, check all that apply: o abcess o pneumothorax 9c. Number of cauterizations for this tumor: o hemorrahage o tumor seeding 0 1 o 2 о З o 4 05 06 o other, specify:


Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				

IVa

Diagram of the Liver

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII




FO	Study 6673	Case #		Revision
Ablation	Freatment Form		10d. Indicate Valley I	_ab Cooled Tip
[ΙΕΝΟΤΑΡΡΙ	ICABLE SKIP AND COM	PLETELAST PAGEL	Rf Ablation needl	es utilized:
<u>[11 110171111</u>			o 1 single, 2 cm t	ip
			o 2 single, 3 cm t	ip
10. Tumor	(Record tumor nu	imber per diagram)	o 3 cluster, 3 pro	ng, 2.5 cm tip
10a.	Number of ablation	s this session within thi		blications encountered?
			o No o Yes	
10b.	Number of prior RF	A sessions for this tume		
10a Nur	nber of cauterizations	for this tymory	o abcess	o pneumothorax
			o hemorrahage	o tumor seeding
0 1	02 03 04	05 06	o other, specify:	
				· · · · · · · · · · · · · · · · · · ·
Ablatio Numbe		Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII




-O :	Study 6673	Case #	Revision
	Treatment Form	PLETE LAST PAGE]	11d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized:
11. Tumor	(Record tumor n	umber per diagram)	o 1 single, 2 cm tip o 2 single, 3 cm tip o 3 cluster, 3 prong, 2.5 cm tip
11a. 🗌	Number of ablation	ns this session within this t	umor 11e. Were any complications encountered?
		A sessions for this tumor	If yes, check all that apply: o abcess o pneumothorax
	mber of cauterizations		o hemorrahage o tumor seeding o other, specify:
Ablatio	n Baseline	Treatment Duration	One Minute Post Treatment Number of

Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII




۶FO	Study 6673	Case # _		Revision
	Freatment Form ICABLE SKIP AND COM	PLETE LAST PAGE]	12d. Indicate Valley Rf Ablation need o 1 single, 2 cm	les utilized:
12. Tumor	(Record tumor nu	ımber per diagram)	o 2 single, 3 cm o 3 cluster, 3 pro	•
12a. 📖		is this session within th	o No o Yes	blications encountered?
	nber of cauterizations		or <u>If yes, check all t</u> o abcess o hemorrahage o other, specify:	o pneumothorax
Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions
1				

Number	impedance (K)	(minutes)	Needle Insertions
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

12f. Mark location cauterizations on diagram with a "c".



"copyright 2005"


Study 6673 Case # _____ Revision Ablation Treatment Form 13d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: [IF NOT APPLICABLE SKIP AND COMPLETE LAST PAGE] o 1 single, 2 cm tip o 2 single, 3 cm tip 13. Tumor (Record tumor number per diagram) o 3 cluster, 3 prong, 2.5 cm tip 13e. Were any complications encountered? 13a. Number of ablations this session within this tumor o No o Yes If yes, check all that apply: 13b. Number of prior RFA sessions for this tumor o abcess o pneumothorax o tumor seeding 13c. Number of cauterizations for this tumor: o hemorrahage o 1 02 03 04 05 06 o other, specify:

Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				

Diagram of the Liver

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



O si	tudy 6673	Case # _		Revision	
NOTAPPLIC		<u>1</u> OMPLETE LAST PAGE] r number per diagram)	Rf Ablation needl o 1 single, 2 cm t o 2 single, 3 cm t	 14d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: o 1 single, 2 cm tip o 2 single, 3 cm tip 	
14a. 🛄 I	Number of abla	tions this session within th	is tumor 14e. Were any comp o No o Yes		
14c. Numb	er of cauterizati	RFA sessions for this tum ons for this tumor: 04 05 06	o abcess o hemorrahage o other, specify:	o pneumothorax	
Ablation Number	Baseline Impedance (R	Treatment Duration	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions	
1					
2 3					
4					
5					

Diagram of the Liver

*Couinaud Segments

1 Segment I

6

7


8

9

10

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

14f. Mark location cauterizations on diagram with a "c".




FO Study 6673 Case #	Revision
Ablation Treatment Form	15d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: o 1 single, 2 cm tip
15. Tumor 🗌 (Record tumor number per diagram)	o 2 single, 3 cm tip o 3 cluster, 3 prong, 2.5 cm tip
15a. Number of ablations this session within this tumor	15e. Were any complications encountered? o No o Yes
15b. Number of prior RFA sessions for this tumor	If yes, check all that apply: o abcess o pneumothorax
15c. Number of cauterizations for this tumor: o 1 o 2 o 3 o 4 o 5 o 6	o hemorrahage o tumor seeding o other, specify:

Ablation Number	Baseline Impedance (R)	Treatment Duration (minutes)	One Minute Post Treatment Temperature(°C)	Number of Needle Insertions
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



FO	Study 6673	Case #	Revision
Comments:			
Signature of	person responsible for the data ¹	Date form completed	d ³ (mm-dd-yyyy)
		2	
Signature of	person entering data onto the web	2	

F2 ACRIN 6673 RFA-HCC Follow-up Form	ACRIN Study 6673 PLACE LABEL HERE Institution Institution No
If this is a revised or corrected form, please $\sqrt{ ext{box}}$.	Participant Initials Case No
Instructions: The F2 form is completed at 6, 9, 12, 15 and 18 mor submitted via the ACRIN website.	nths post initial RFA procedure by the Research Associate, and
 1. Did the participant return for the scheduled follow-up? [1] O No (Answer 1a, and 1b) O Yes (Answer 1c) 1a. If no, specify reason: [2] O Participant refusal O Participant unable to be contacted O Unable to be performed and rescheduled O Other, specify:[3] 1b. Date of last contact:	 4. Participant status: [13] Alive (Complete 4a) Dead (Complete 4a, 4c, and 4d) Unknown/unable to contact (Complete 4a) 4a. Was the liver: [14] Transplanted (Complete 4b) Resected (Complete 4b) Resected (Complete 4b) Neither Unknown 4b. Date of transplant / resection:
2. Date of follow-up contact or attempt:	(mm-dd-yyyy) [17] Check if date of death unknown:
 3. RFA Follow-up Time Period: [8] O 6 months O 9 months O 12 months O 15 months O 18 months O Other, specify:[9] 	 Date of death unknown [18] 4d. Cause of death: [19] O Progressive/persistent cancer O Complications of protocol treatment O Progressive cirrhosis O Other, specify:
 3a. Last RFA session date: 	 5. Performance status (Zubrod Scale) [21] O Fully active O Ambulatory, capable of light work O In bed less than 50% of the time, capable of self-care, but not of work activities O In bed greater than 50% of the time, capable of only limited self care O Bedridden O Not evaluated O Unknown

	ACRIN 6673 RFA-HCC Follow-up Form	ACRIM PLACE I	Study 6673
		Institution	Institution No.
lf	his is a revised or corrected form, please \sqrt{box} .	Participant Initials	Case No
6.	Any non-protocol treatment started during this follow-up time period: [22]	10a. If no to re-ablat	ion, provide reason:
	O No (proceed to Q7) O Yes (If yes, complete Q6a)	(Check all that	
	O Unknown (proceed to Q7)		nor exceeds 5 cm $_{[41]}$
	6a. <u>Treatment</u> <u>Date started</u>		e adjacent to vital structures [42]
	(check all that apply) (mm-dd-yyyy)		of extrahepatic tumor _[43]
	□ Chemotherapy [23][24]	clinically in	ally feasable / not dicated [44]
	Start date of Chemotherapy unknown [25]		remote intrahepatic tumor visible [45
	Radiation to Non-Study _[26] [27] Site,		ne week of CT Scan? [46]
	Start date of Radiation to Non-Study Site unknown [28]	O No, specify reaso	[]
	Specify Non-Liver site:[29]	O Yes (answer Q8a	
	☐ Other treatment, [30] [31]	11a. Date drawn:	(mm-dd-yyyy)
	Other treatment start date unknown [32]		
	Specify treatment:[33]		e: ng/ml _[49]
7.	 Were there any tumor biopsies performed during this time period? [34] O No (proceed to Q8) O Yes (Answer Q7a and Q7b, submit per Sec 11.3 of the protocol) O Yes, previously submitted (Answer Q7a and Q7b) O Unknown 7a. Date of biopsy: (mm-dd-yyyy) [35] Date of biopsy unknown [36] 7b. Type of procedure [37] O FNA 	since the pre O No O Yes, lab	lab value increased or decrease evious follow-up visit? [50] value increased value decreased
	O Core needle		
σ.	Is there evidence of local intrahepatic tumor on the corresponding CT exam for this visit? [38] O No O Yes O Indeterminate	Name of person responsib	ble for the data
9.	Is there evidence of remote intrahepatic tumor on the corresponding CT exam for this visit? [39] O No O Yes	 Date Form Completed (mn	[53] n-dd-yyyy)
10	Will/has this participant been scheduled for reablation? [40] O No O Yes	Name of person entering o	data on web

F1 RFA-HCC	ACRIN Study 6673 PLACE LABEL HERE		
Follow-up Form	Institution Institution No		
If this is a revised or corrected form, indicate by checking box.	Patient's Initials Patient's I.D. No		
Instructions: The F1 form is completed at day 1, post initial RFA procedure by the Research Asso			
1. RFA Follow-up Time Period:	4. Cause of death:		
O 1 1 day	O 0 Alive		
O 2 1 week	O 1 Progressive/persistent cancer		
O 3 1 month	O 2 Complications of protocol treatment		
O 4 0-3 months	O 3 Both cancer and protocol treatment		
O 5 3-6 months	O 4 Progressive cirrhosis		
O 6 6-9 months	O 5 Other, specify		
O 7 4-12 months	O 99 Unknown		
O 8 12-15 months			
O 9 15-18 months	5. Tumor number:		
O 10 Other, specify:	0 1 0 3 0 5 0 7		
1a. Reason for follow-up:	0 2 0 4 0 6 0 8		
O 1 Telephone contact			
O 2 Every 3 month visits	6. Performance status (Zubrod Scale)		
O 3 RFA treatment	O 0 Fully active		
O 4 Post-ablation CT scan	O 1 Ambulatory, capable of light work		
	O 2 In bed less than 50% of the time, capable		
1b. RFA treatment date:	of self-care, but not of work activities		
	O 3 In bed greater than 50% of the time,		
(mm-dd-yyyy)	capable of only limited self care		
	O 4 Bedridden		
1c. Date of Post-ablation CT scan:	O 98 Not evaluated		
	O 99 Unknown		
(mm-dd-yyyy)			
1d. Were any adverse events reported	7. Did the participant return for the scheduled follow-up?		
during this time period:	O 1 No (specify reason, STOP and sign form)		
O 1 Yes	O Participant refusal		
O 2 No	O Participant unable to be contacted		
	O Unable to be performed and rescheduled		
If <u>ves</u> , specify date:	O 2 Yes		
(mm-dd-yyyy)	O Completed		
2. Date of evaluation:	O Incomplete, will return on:		
(mm-dd-yyyy)			
3. Patient status:	·_·		
O 1 Alive	(mm-dd-yyyy)		
	O Incomplete, return date unknown		
O 2 Transplanted	if <u>No</u> - specify reason:		
O 3 Dead	· ·		
O 4 Lost to follow-up (unable to contact)			
3a. Status Date:(mm-dd-yyyy)			
(Date of death if dead, date of transplant if transplanted,			
or last date known alive if alive or lost.)			

F1	Study	6673	Case #		Revis	ion
1 2 3 98		l elevated				
<u>Lat</u>	bs Evaluation	Lab Value		t <mark>t (mm-dd-yyyy)</mark> uired for all labs)	Normal Range LOW (required for all abnormal results)	Normal Range HIGH (required for all abnormal results)
	Platelets	ml				
	PT	seconds				
	PTT	seconds	·			
	INR	L. mg/dl				
	Serum Crea	atinine mg	/dl			
	GGT	u/I				
	LDH	mg/dl				
	AFP	ng/ml				
	SGOT	u/I				
	SGPT	u/I				
	Total bilirub	in 🔄 . 🔄 mg/dl				
	Sodium	meg/dl				
	Potassium	L. meq/l				
	Chloride	mea/l				
	Glucose	mg/dl				
	BUN	mg/dl				
	Calcium	L. mg/dl	-			
	Phosphoru	s mg/dl	-			
	Total Protei	n 🔄 gm/dl				
	Albumin	L. gm/dl				
	Ammonia	g/dl				
	Hgb	L. g/dl				
	Hct	ml/dl	-			
	Wbc	L. k/mm	n ³			
	Beta hCg	L. k/mm	n ³			

F1	Study 667	'3 Ca	ase #	Revis	ion
[F 1 c 2 c 3 c 98 n	ost RFA Treatment I Performed within 14 done, within normal lone, abnormal eleva done, abnormal dep ot done inknown	limits ated	ns:		
<u>Labs</u>	<u>Evaluation</u>	Lab Value	<u>Date of test (mm-dd-yyyy)</u> (date is required for all labs)	<u>Normal Range</u> LOW (required for all abnormal results)	<u>Normal Range</u> HIGH (required for all abnormal results)
	Platelets	ml			
	PT	seconds			
	PTT	seconds	• •		
	INR	L. mg/dl			
	Serum Creatinine	L mg/dl			
	GGT	u/I	• •		
	LDH	mg/dl	· · ·		
	AFP	ng/ml	·		
	SGOT	u/I	· ·		
	SGPT	u/I	· ·		
	Total bilirubin	L. mg/dl	· ·		
	Sodium	meg/dl	·		
	Potassium	L. meq/l	·		
	Chloride	mea/l	·		
	Glucose	mg/dl	·		
	BUN	mg/dl	·		
	Calcium	L. mg/dl	·		
	Phosphorus	L. mg/dl	·		
	Total Protein	gm/dl	·		
	Albumin	gm/dl	··		
	Ammonia	g/dl	··		
	Hgb	g/dI	··		
	Hct	ml/dl	· ·		
	Wbc	k/mm³	••		

F1 St	udy 6673	Case #	Revision	
fol (non-protocol treatm low-up periods: D 1 No D 2 Yes (if yes, com D Unknown	nent started during this		
10a.	Treatment Hormones	<u>Date started (mm-dd-yyyy)</u> 	l 	
	Chemotherapy		_	
	Radiation to Non-Study Site, Specify:			
	Other treatment Specify:	,		
Comments:				
Signature of pe	erson responsible for the	data ¹	Date form completed ³ (mm-dd-yyyy)
Signature of pe	erson entering data onto	the web ²		

"copyright 2005"

Cantral Reader	ACRIN Study 6673
	PLACE LABEL HERE
Interpretation Form	
	Institution Institution No
If this is a revised or corrected form, please \sqrt{box} .	Participant Initials Case No
Instructions: The central reader is to review the abdominal scans for to document tumors and tumor descriptors. All dates are reported a noted. This form will be completed and data entered at ACRIN head	s MM/DD/YYYY. All responses are required unless otherwise
The ACRIN Case Number and Follow-Up Time Period must be reco	orded on all pages of this form.
Section I.	Section II.
1. RFA Follow-up Time Period [1] 0 1 Pre-enrollment 0 2 Baseline (initial post-ablation) 0 3 3 Month 0 4 6 Month 0 5 9 Month 0 6 12 Month 0 7 15 Month 0 8 18 Month 0 88 Other, specify [2] 2. Date of Scan:	4. Is there evidence of new Extrahepatic Tumor(s)? [15] 1 No (skip Q4a) 2 Yes (complete Q4a and Section III) 4a. Specify location(s): [mark all that apply: = 1 Not Marked, [= 2 Marked] Adrenal gland [16] Kidney [17] Lung [18] Lymph node [19] Musculoskeletal [20] Pancreas [21] Peritoneum [22] Spleen [23] Abdominal wall [24] Other, [25] specify [26]

ACRIN 6673 Central Reader Interpretation Form	ACRIN Study 6673 PLACE LABEL HERE	
If this is a revised or corrected form, please \sqrt{box} .	Institution Participant Initials	
Section III.		

TUMOR REPORT

* Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.

** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

*Tumor Number	Tumor Size (cm)	Ablation Status Per Follow-Up Time Period	*Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked]	Tumor Status	Are there additional tumors to report?	**Local read Tumor match Number
[27]	[28]	[29] O 1 Ablated O 2 Not ablated	$ \begin{array}{ c c c c c } & & & & & & & & \\ \hline & & & & & \\ \hline & & & &$	[39] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[40] O 1 No O 2 Yes	[41]
	··	O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
		O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	··	O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
		O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII Segment IVB Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	

ACRIN 6673 Central Reader Interpretation Form If this is a revised or corrected form, please √box. <u>TUMOR F</u> * Tumor numbering and location(s) must be the same on every cen ** Local read tumor match number is to be completed after the last			ntral reader form across all follow-up time periods.				
	Tumor found by the Tumor Size (cm)		*Tumor Lo Couinaud Live [mark all that apply:] = 1 Not Marked,] = 2 Marked]	cation	Tumor Status	Are there additional tumors to report?	**Local read Tumor match Number
	·	O 1 Ablated O 2 Not ablated	Segment II Segment III	Segment V Segment VI Segment VII Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment II	Segment V Segment VI Segment VII Segment VII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment I Segment II Segment III Segment IVA Segment IVB	Segment V Segment VI Segment VII Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment I Image: Constraint of the segment II Image: Constraint of the segment III Segment IVA Image: Constraint of the segment IVA Image: Constraint of the segment IVA	Segment V Segment VI Segment VII Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment I Segment II Segment III Segment IVA Segment IVB	Segment V Segment VI Segment VII Segment VII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	

CX ACRIN 6673 Central Reader Interpretation Form	ACRIN Study 6673 PLACE LABEL HERE				
If this is a revised or corrected form, please \sqrt{box} .	Institution Institution No Participant Initials Case No				
TUMOR REPORT * Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.					

** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

*Tumor Number	Tumor Size (cm)	Ablation Status Per Follow-Up Time Period	*Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked]	Tumor Status	Are there additional tumors to report?	**Local read Tumor match Number
	··	O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	
	·	O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O1No O2Yes	
		O 1 Ablated O 2 Not ablated	Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA Segment VIII Segment IVB Segment VIII	O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	O 1 No O 2 Yes	

ACRIN 6673 Central Reader Interpretation Form	ACRIN Study 6673 PLACE LABEL HERE Institution		
Instructions:	Participant Initials Case No		
1) Mark tumor location(s) on the diagram by encircling the tumor number. Example for Tumor #1 (1) 2) Mark cauterization location(s) on the diagram with a "c" encircled. Example (C) 3) Tumor numbering and locations must be consistent throughout central reader interpretation across all Image: the transformation of the transform	IVa III		

CX ACRIN 6673 Central Reader Interpretation Form	ACRIN Study 6673 PLACE LABEL HERE				
If this is a revised or corrected form, please \sqrt{box} .	Institution Institution No Participant Initials Case No				
Section IV.					
Comments:					
	[42]				
[43] Reader Initials	Date form completed (mm-dd-yyyy)				
[45] Initials of person completing form					
Section V: (ACRIN personnel only)					
This section is completed after tumor matching, by the ACRIN	IRA.				
Adjudicator review required if Central reader and Local reade	r disagree about:				
1. the presence of disease.					
 the size of tumors (tumor size must be within 50% of the size recorded, i.e: if the local measure was 2 cm and the central was >3cm or <1cm then it would require adjudication). 					
3. the number of tumors.	3. the number of tumors.				
 the couinaud segment location of tumors (tumors must be in the same or adjacent segment, i.e: if the local was in segment II and the Central was in segment V then it would require adjudication) 					
5. the Central reader found a tumor missed by the Local reader.					
6. the Local reader found a tumor missed by the Central reader.					
 Is adjudicator review required? [46] No Yes 					
Initials of person responsible for the data	Date form completed (mm-dd-yyyy)				

CD ACRIN 6673 Chest CT Imaging Form	ACRIN Study 6673 PLACE LABEL HERE Institution Institution No
If this is a revised or corrected form, please \sqrt{box} .	Participant Initials Case No.
nstructions: The CD form is completed by the Site Radiologis nonth visit. This form is submitted via the ACRIN website.	st to document findings on the Chest CT scan performed at the 18
 Was a chest CT scan performed at 18 months? [1] 	8. Indicate the results of this scan
O No (Answer Q2)	O Negative (Complete Q8a) [10]
O Yes (Skip to Q3)	8a. If negative, indicate clinical significance [11]
	O No significant abnormalities
2. If no, give reason (then sign and date form) [2]	O Minor abnormalities not suspicious
O Scheduling problems	for pulmonary metastases
O Equipment failure	O Significant abnormalities not suspicious for
O Participant refusal O Medical reasons	pulmonary metastases
O Injection site complications	O Positive (Complete Q8b) [12]
O Claustrophobia	8b. If positive, indicate overall suspicion
O Participant withdrew consent	for pulmonary metastases [13]
O Progressive disease	O Low suspicion
O Participant death	O Intermediate suspicion
O Other, specify[3]	O Moderately high suspicion
O Unknown	O High suspicion
3. Date of Chest CT scan / ////////	O Inadequate/suboptiomal (Complete Q8c) [14]
(mm-dd-yyyy)	8c. If inadequate/suboptimal, indicate reason [15]
	O Not enough of body imaged
I. Date of Chest CT interpretation	O Noisy images
(Date CT scan reviewed by Study Radiologist)	O Patient motion
	O Metal artifact O Other, specify
(<i>mm-dd-yyyy</i>) [5]	O Other, specify [10
5. Reader ID	
 Was a Helical Chest CT scan performed with slice thickness of 5 – 8 mm? 	
O No (If no, please submit a PR describing the deviation)	
O Yes	
O Other, specify[8]	
7. Chest CT scan performed [9]	
O With intravenous contrast	
O Without intravenous contrast	

CDD ACRIN 6673 Chest CT Imaging Form If this is a revised or corrected form, please √box.	PLAC	ACRIN Study 6673
Comments:		[17]
Signature of Site Radiologist	- [18]	 Date Form Completed (mm-dd-yyyy)
"Copyright 2008"		6672 CD 02 29 09 2 of

ACRIN 6673 Central Reader Chest CT Interpretation Form If this is a revised or corrected form, please √box. Instructions: The central reader is to complete one C8 form for eac YYYY. All responses are required unless otherwise noted. This form	
1. Protocol timepoint [1] 0 1 Baseline 0 2 18 month 0 88 Other, specify[2] 1a. Date of scan (mm-dd-yyyy) [3] 2. Reader ID [4] Image Quality: 3. Interpretable? [5] 0 1 No (complete 3a, then initial and date form) 0 2 Yes (skip to Q4) 3a. Reason [mark all that apply: $\Box = 1$ Not Marked, $\[nothinderlines] = 2$ Marked] \square Motion [6] \square Artifacts [7] \square Contrast media [8] \square DICOM header [9] \square Lost images [10] \square Poor S/N [11] \square Incomplete anatomic coverage [12] \square Other [13] specify [14]	 Is tumor present? [15] 1 No (Initial and date form) 2 Yes (complete Q4a) 3 Indeterminate (complete Q4a) 4a. Location of tumor (excluding extra-thoracic) [mark all that apply: = 1 Not Marked, f = 2 Marked] Pulmonary [16] Mediastinum [17] Bone [18] Other [19] specify [20]
Comments: [22] Reader Initials [24] Initials of person completing form	[21]


C2 ACRIN 6673 Initial Imaging Form ACRIN Study 6673 PLACE LABEL HERE					
	Institution Institution No				
If this is a revised or corrected form, please \sqrt{box} .					
Initial Imaging Form					
	y the Study Radiologist (the radiologist performing the RFA).				

1.	Reader ID#:	6.	Imaging findings of cirrhosis present? O No (skip to Q7)
2.	Type of abdominal scan		O Yes (complete Q6a)
	O CT O MRI		6a. Check <u>all</u> that apply:
	2a. Date of abdominal scan:		Nodular LiverHepatic atrophy/hypertrophy
			Portal varices
3.	Date of Chest CT Scan:		SplenomegalyAscites
4.	Is there evidence of metastatic disease on Chest CT?	7.	Number of per protocol tumors for ablation present:
	O No O Yes		0 1 0 2 0 3
5.	Description of the protocol?		Are there hypervascular lesions (non-protocol lesions) present < 1 cm?
	O No (Ultrasound not being used as guidance technique for ablation) O Yes		O No O Yes

A copy of page 2 (with case specific label) is mailed to the Data Management center.

American College of Radiology ACRIN 6673/Data Management 1818 Market Street/Suite 1600 Philadelphia, PA 19103

be affixed to the form in the designated area.



Comments:

Signature of person responsible for the data 1

Signature of person entering data onto the web 2

Date form completed 3

20

(mm-dd-yyyy)

	ACRIN Study 6673
Al Assessment of Tumor Resectability	PLACE LABEL HERE
If this is a revised or corrected	Institution Institution No
form, indicate by checking box.	Patient's Initials Patient's I.D. No
Instructions: This form must be completed by the Surgical Or	ncologist.
1. Is the participant a candidate for liver resection?	
O No (complete 1a)	
O Yes	
1a. Reason: (Select all that apply)	
Tumors in unresectable location.	
Co-morbid disease making the patient a poo	or surgical candidate.
Insufficient hepatic reserve.	
O	
Comments:	
	20
Signature of Surgical Oncologist ¹	Date form completed ³ 20 (mm-dd-yyyy)
Signature of person entering data onto the web ²	

ACRIN 6673	
	ACRIN Study 6673
Adjudicator Interpretation Form	
[Abdominal Scan]	PLACE LABEL HERE
	Institution Institution No
	Participant Initials Case No
If this is a revised or corrected form, please \sqrt{box} .	
Instructions: The adjudicator is to review the abdominal scans for each case tumors and tumor descriptors. All dates are reported as MM/DD/YYYY. All re and data entered at ACRIN headquarters. The ACRIN Case Number and Follow-Up Time Period must be reco	esponses are required unless otherwise noted. This form will be completed
Section I.	Section II.
1 PEA Follow up Time Period	4 Is there evidence of new Extrahenatic Tumor(s)?
1. RFA Follow-up Time Period 0 1 Pre-enrollment 0 2 Baseline (initial post-ablation) 0 3 3 Month 0 4 6 Month 0 5 9 Month 0 6 12 Month 0 7 15 Month 0 8 18 Month 0 8 Other, specify 2. Date of Scan:	4. Is there evidence of new Extrahepatic Tumor(s)? [15] 0 1 No (skip Q4a) 0 2 Yes (complete Q4a and Section III) 4a. Specify location(s): [mark all that apply:] = 1 Not Marked, [] = 2 Marked] 0 Adrenal gland [16] 1 Lung [18] 1 Lymph node [19] 1 Musculoskeletal [20] 1 Peritoneum [22] 2 Spleen [23] 1 Abdominal wall [24] 1 Other, [25] specify [26]

	I ACRIN 6673
5	Adjudicator Interpretation Form
	ACRIN 6673 Adjudicator Interpretation Form [Abdominal Scan]

If this is a revised or corrected form, please \sqrt{box} .

ACRIN Study 6673

PLACE LABEL HERE

Institution ____

Institution No. —

Participant Initials_____ Case No. __

Section III.

TUMOR REPORT

* Tumor numbering and location(s) must be consistent throughout the adjudicator reader interpretation - per follow-up time periods.

** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

*Tumor Number	Tumor Size (cm)	Ablation Status Per Follow-Up Time Period	*Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked]	Tumor Status	Are there additional tumors to report?	**Local read Tumor match Number
[27]	[28]	[29] O 1 Ablated O 2 Not ablated	$ \begin{array}{ c c c c c } & & & & & & & & & \\ \hline & & & & & & & \\ & & & &$	[39] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[40] O 1 No O 2 Yes	[41]
[42]	[43] 	[44] O 1 Ablated O 2 Not ablated	Segment I Segment V [50] Segment II [46] Segment VI [51] Segment III [47] Segment VII [52] Segment IVA [48] Segment VIII [53] Segment IVB [49] Segment VII [53]	[54] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[55] O 1 No O 2 Yes	[56]
[57]	[58] 	[59] O 1 Ablated O 2 Not ablated	$ \begin{array}{ c c c c c c } & & & & & & & & \\ \hline & & & & & & \\ \hline & & & &$	0 2 Tumor present	[70] O 1 No O 2 Yes	[71]
[72]	[73]	[74] O 1 Ablated O 2 Not ablated	Segment I [75] Segment V [80] Segment II [76] Segment VI [81] Segment III [77] Segment VII [82] Segment IVA [78] Segment VIII [83] Segment IVB [79] Segment VIII [83]	O_2 Tumor present	[85] O 1 No O 2 Yes	[86]
[87]	[88] ·	[89] O 1 Ablated O 2 Not ablated	Segment I [90] Segment V [95] Segment II [91] Segment VI [96] Segment III [92] Segment VII [97] Segment IVA [93] Segment VIII [98] Segment IVB [94] Segment VIB [94]	[99] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[100] O 1 No O 2 Yes	[101]

ACRIN 6673 Adjudicator Interpretation Form [Abdominal Scan]			Institution	ACRIN Stu PLACE LAI	BEL HER		
If this is a revi	ised or corrected fo	rm, please √box.			itials		
* Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods. ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.							
*Tumor Number	Tumor Size (cm)	Ablation Status Per Follow-Up Time Period	*Tumor Lo Couinaud Live [mark all that apply: = 1 Not Marked, = 2 Marked]		Tumor Status	Are there additional tumors to report?	**Local read Tumor match Number
[102]	[103] 	[104] O 1 Ablated O 2 Not ablated	Segment I [105] Segment II [106] Segment III [107] Segment IVA [108] Segment IVA [108] Segment IVA [108]	Segment V _[110] Segment VI _[111] Segment VII _[112] Segment VIII _[113]	[114] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[115] O 1 No O 2 Yes	[116]
[117]	[118] 	[119] O 1 Ablated O 2 Not ablated	Segment I [120] Segment II [121] Segment III [122] Segment IIVA [123] Segment IVA [123] Segment IVA [123]	Segment V [125] Segment VI [126] Segment VII [127] Segment VIII [128]	0 / T /	[130] O 1 No O 2 Yes	[131]
[132]	[133]	[134] O 1 Ablated O 2 Not ablated	Segment I [135] Segment II [136] Segment III [137] Segment IVA [138] Segment IVA [138] Segment IVA [139]	Segment VI [141]	O 1 Tumor absent	[145] O 1 No O 2 Yes	[146]
[147]	[148] 	[149] O 1 Ablated O 2 Not ablated		Segment V [155] Segment VI [156] Segment VII [157] Segment VIII [158]	[159] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[160] O 1 No O 2 Yes	[161]
[162]	[163]	[164] O 1 Ablated O 2 Not ablated	Segment I [165] Segment II [166] Segment III [167] Segment III [167] Segment IIVA [168] Segment IVA [168] Segment IVA [169]	Segment VI [171]	[174] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate	[175] O 1 No O 2 Yes	[176]

ACRIN 6673
Adjudicator Interpretation Form
[Abdominal Scan]

If this is a revised or corrected form, please \sqrt{box} .

ACRIN Study 6673

PLACE LABEL HERE

Institution ____

Institution No. —

Participant Initials_____ Case No. __

TUMOR REPORT

* Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.

** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

*Tumor Number	Tumor Size (cm)	Ablation Status Per Follow-Up Time Period	*Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked]	Tumor Status	Are there additional tumors to report?	**Local read Tumor match Number
[177]	[178]	[179] O 1 Ablated O 2 Not ablated	$ \begin{array}{ c c c c c c c } & & & & & & & & & & & & & & & & & & &$	O 1 Tumor absent O 2 Tumor present	[190] O 1 No O 2 Yes	[191]
[192]	[193] 	[194] O 1 Ablated O 2 Not ablated	Segment I [195] Segment V [200] Segment II [196] Segment VI [201] Segment III [197] Segment VII [202] Segment IVA [198] Segment VII [203] Segment IVA [199] Segment VII [203]	O 1 Tumor absent	[205] O 1 No O 2 Yes	[206]
[207]	[208] 	[209] O 1 Ablated O 2 Not ablated	$\begin{tabular}{ c c c c c c c } \hline Segment I_{[210]} & Segment V_{[215]} \\ \hline Segment II_{[211]} & Segment VI_{[216]} \\ \hline Segment III_{[212]} & Segment VII_{[217]} \\ \hline Segment IVA_{[213]} & Segment VII_{[218]} \\ \hline Segment IVB_{[214]} \\ \hline \end{tabular}$	O 1 Tumor absent	[220] O 1 No O 2 Yes	[221]
[222]	[223]	[224] O 1 Ablated O 2 Not ablated	$ \begin{array}{ c c c c c c c } \hline Segment I_{[225]} & Segment V_{[230]} \\ \hline Segment II_{[226]} & Segment VI_{[231]} \\ \hline Segment III_{[227]} & Segment VII_{[232]} \\ \hline Segment IVA_{[228]} & Segment VII_{[233]} \\ \hline Segment IVB_{[229]} \\ \hline \end{array} $	O 1 Tumor absent	[235] O 1 No O 2 Yes	[236]
[237]	[238] 	[239] O 1 Ablated O 2 Not ablated	Segment I Segment V [245] Segment II Segment VI [246] Segment III Segment VI [247] Segment IVI Segment VI [247] Segment IVI Segment VII [247] Segment IVA Segment VII [247] Segment IVA [243] Segment VIII Segment IVB [244] Segment VIB	O 1 Tumor absent	[250] O 1 No O 2 Yes	[251]

ACRIN 6673 Adjudicator Interpretation Form [Abdominal Scan]	ACRIN Study 6673 PLACE LABEL HERE Institution Institution No
If this is a revised or corrected form, please \sqrt{box} .	Participant Initials Case No
Section IV.	
[253	[252] 3] [254]
Reader Initials	Date form completed (mm-dd-yyyy)
Initials of person completing form	

ACRIN 6673 Adjudicator Interpretation Form [Chest CT]	ACRIN Study 6673 PLACE LABEL HERE Institution Institution No
If this is a revised or corrected form, please \sqrt{box} .	Participant Initials Case No
Instructions: This data is assessed by the adjudicator at ACRIN He form. All dates are reported as MM/DD/YYYY. All responses are req	
1. Protocol timepoint [1] 0 1 Baseline 0 2 18 month 0 88 Other, specify	4. Is tumor present? [15] ○ 1 No (Initial and date form) ○ 2 Yes (complete Q4a) ○ 3 Indeterminate (complete Q4a) 4. Location of tumor (excluding extra-thoracic) [mark all that apply: = 1 Not Marked, = 2 Marked] □ Pulmonary [16] □ Mediastinum [17] □ Bone [18] □ Other [19] specify [20]
Comments:	
[22] Reader Initials	[21] [23] Date form completed (mm-dd-yyyy)
Initials of person completing form	

APPENDIX II

REGISTRATION/E	ELIC	GIBILITY CHECK (Page 1 of 3)		
ACRIN 6673				
ACRIN Institution #	¥	ACRIN Case #		
Eligibility Requirements: Inclusion Criteria - a response coded other than what is prompted renders a participant ineligible for enrollment.				
(Y)	1.	Biopsy proven cirrhosis, or typical findings of cirrhosis by CT scan.		
(Y)	2.	Hepatocellular carcinoma (HCC) proven by: (Check all that apply) ($\Box 1 = No, \boxtimes 2 = Yes$)		
		Biopsy		
		Barcelona imaging criteria [see Appendix VIII, #3]		
		Barcelona combined criteria [see Appendix VIII, #3]		
		Tumor growth criteria [see Appendix VIII, #4]		
	3.	Hepatic tumor burden meeting the Milan Criteria.		
		O 3 or fewer tumors ≤ 3.0 cm or		
		O a single tumor > 3.0 cm but \leq 5 cm in diameter		
(Y)	4.	All identified tumors are treatable by percutaneous RFA: all tumors are ≥ 1 cm from the main, right and left portal veins and all tumors are ≥ 1 cm from hollow viscera.		
(0-2)	5.	Record performance scale as defined by the Zubrod Performance Scale. [see Appendix V and 5.3.6]		
(Y)	6.	Serum creatinine ≤ 2.0 mg/dl.		
(Y)	7.	Chest and abdominal CT scan within 60 days of initial RFA treatment.		
(Y)	8.	Aspirin and nonsteroidal anti-inflammatory medications, anti-platelet medications, or wafarin has been discontinued for a time period that is appropriate given the drug half-life or its known anti-platelet activity (e.g., aspirin for 7 days and ibuprofen 24 hours) prior to the scheduled RFA.		
(Y)	9.	All laboratory requirements as described in section 5.3.3 of the protocol have been met.		
Eligibility Requirer		ts: <u>Exclusion Criteria</u> - a response coded other than that prompted renders a enrollment.		
(N)	10.	Participant has had prior treatment for HCC by any method. [see Section 5.1.12]		
(N)		. Surgical candidate. [see Appendix IX]		

- (N) 12. Hepatic or portal vein tumor invasion.
 - (N) 13. Extrahepatic tumor.

REGISTRATION/ELIGIBILITY CHECKLIST

ACRIN 6673

ACRIN Case #_____

	_(N)	14. Active infection. [see Section 5.2.12]
	_(N)	15. History of cholendochoenteric anastomosis and or spincterotomy of duodenal papilla.
	_(N)	16. Absolute contraindication to intravenous iodinated contrast. [see Section 5.2.15]
The following o	questio	ns will be asked at Study Registration:
	1.	Name of institutional person registering this case.
	_(Y)2.	Has the Eligibility Checklist (Inclusion/Exclusion Q1-16) been completed?
	_(Y)3.	Is the participant eligible for this study?
/	_ 4.	Date the study-specific Consent Form was signed (mm/dd/yyyy) (must be prior to study entry)
	_ 5.	Participant Initials (last, first): Numeric number may be coded other than the assigned case number, ####.
	6.	Verifying Physician (Site PI)
	_ 7.	Participant's ID Number (optional: this is an institution's method of tracking participant to a case number; code 99999)
/	8.	Date of Birth (mm-dd-yyyy)
	_ 9.	Ethnic category 1 Hispanic or Latino 2 Not Hispanic or Latino 9 Unknown
	10.	 Race (Check all that apply. □ 1 = No, ⊠2 = Yes) American Indian or Alaskan Native Asian Black or African American Native Hawaiian or other Pacific Islander White Unknown
	_ 11.	Gender 1. Male

2. Female (Complete question 20, negative pregnancy test...)

REGISTRATION/ELIGIBILITY CHECKLIST

ACRIN 6673 ACRIN Case # 12. Participant's country of residence (if country of residence is other, proceed to Question 13 for completion) 1 United States (Complete question 14, Zip code) 2 Canada 3 Other (Complete question 13, Other country, specify) 9 Unknown 13. Other Country, specify (completed if Q12 is coded 'Other') 14. Zip code (5 digit code, completed if Q12 is coded 'United States') 15. Participant's Insurance Status 0 Other 1 Private Insurance 2 Medicare 3 Medicare and Private Insurance 4 Medicaid 5 Medicaid and Medicare 6 Military or Veterans Administration 7 Self pay 8 No means of payment 9 Unknown/Decline to answer 16. Will any component of the participant's care be given at a military or VA facility? 1 No 2 Yes 9 Unknown 17. Initial RFA Treatment Date (mm/dd/yyyy) / / / ___/____ 18. Registration Date (mm/dd/yyyy) 19. MELD Score: O Score > 25O Score 15 – 25 O Score < 15 (\mathbf{Y}) 20. If female, negative pregnancy test within 24-hours of RFA treatment? (Y/N) 21.Does the participant have a pacemaker? Study Participant Signature: _____ Date: ____/____

Completed by:	_Date form completed:	//
(Research Associate, Investigator Designee, or Principal Investigator)		

Signature of person entering data onto the Web _____

(Page 3 of 3)